Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

People claim the viral "natural Mounjaro" drink — honey, lemon, water, and ginger — makes you lose weight. Here's what an ...

Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

A mom of two is getting her exercise by cleaning her house. It's something Melissa Floro says she didn't have the energy to ...

Up to 3.4 million eligible patients could benefit from the medication that treats type 2 diabetes and aids weight loss ...